Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway Progressed Pipeline with New Preclinical Data and Scientific Presentations at Leading Industry Conferences SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today reported financial results for the second quarter ended Dec. 31, 2025, and provided a corporate update on its progress. “We have significantly a ...

Strategic alignment announced at the Dubai World Health Expo 2026 combines global healthcare expertise with digital health innovation to explore new comprehensive, workforce wellbeing solutionsABU DHABI, United Arab Emirates and VANCOUVER, BC, Feb. 10, 2026 /PRNewswire/ - Abu Dhabi Health Data Services (ADHDS), part of the M42 group, and TELUS Health, announced a strategic agreement to introduce new personalized employee wellbeing solutions in the UAE that combine wellness, precision medicine and AI-driven ...

In short: SACRAMENTO, Calif., Feb. 9, 2026 /PRNewswire/ -- Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial. Negotiations are moving forward with several pharmaceutical and drug discovery companies. Partnerships and collaborations are imminent. Why? -because Lunai Bioworks operates a closed loop AI system that is truly disruptive (and complementary) to current discovery platforms and that turns complex biology into real-world action in several ways with les ...

Financial Data and Key Metrics Changes - The cash position at December 31 was $131.7 million with no debt, and the company utilized $7.1 million in operating activities during the quarter, indicating a cash runway of more than three years at the current utilization rate [8][9] - Research and development expenses for the quarter were $4.7 million, down from $10.4 million in the same quarter last year, while general and administrative expenses decreased to $2.1 million from $3.1 million [8][9] - The net loss for the quarter was reported at $5.7 million, or $0.06 per share [9] Business Line Data and Key Metrics Changes - The decrease in operating expenses was primarily due to the completion of a large manufacturing campaign for blarcamesine and a reduction in clinical trial activities following the completion of the Anavex 3-71 phase II study in schizophrenia [9] Market Data and Key Metrics Changes - The company is participating in the ACCESS-AD initiative, which aims to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer's disease across Europe, funded by the European Commission [4][51] Company Strategy and Development Direction - The company is focused on advancing its clinical pipeline, particularly the lead candidate oral blarcamesine for early Alzheimer's disease, and is working with regulatory agencies in Europe and the U.S. to develop this treatment option [3][4] - Anavex plans to provide updates on regulatory and clinical trial developments for blarcamesine in other indications, including Parkinson's disease and fragile X syndrome [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of blarcamesine to improve the lives of patients with neurological disorders and emphasized the importance of scalable treatment options with oral administration [10][60] - The company acknowledged the challenges posed by regulatory feedback but remains committed to addressing these through data resubmissions and ongoing clinical trials [4][44] Other Important Information - The company is preparing for a confirmatory phase trial if approved under the Conditional Marketing Authorization (CMA) pathway, which will involve real-world cohorts of paying patients [49][51] - Anavex is also planning to present new scientific findings at upcoming conferences, which may further support its clinical claims [6] Q&A Session Summary Question: Can you provide additional information regarding the rapporteur and co-rapporteur for the re-examination of the CHMP opinion on blarcamesine? - The rapporteurs will be selected from the 27 EU countries [15] Question: What is the timeline for the re-examination process? - The re-examination process is expected to last for the first half of the year, involving a 60 + 60-day period for responses and reviews [16] Question: What additional information will be included in the resubmission to the EMA? - The resubmission will include data from the AD-004 study, A-Clear study population, and correlations of clinical efficacy with brain atrophy reduction [24] Question: Are there any ongoing trials currently? - The only ongoing trials are compassionate use programs for Rett Syndrome and Alzheimer's Disease, with plans for studies in Parkinson's Disease and Fragile X Syndrome [28] Question: How will the ACCESS-AD program involve blarcamesine? - The program will include a placebo-controlled trial of blarcamesine targeting early Alzheimer's patients, focusing on biomarkers and efficacy [51][52]

Financial Data and Key Metrics Changes - The cash position at December 31 was $131.7 million with no debt, and the company utilized $7.1 million in operating activities during the quarter [8][9] - Research and development expenses for the quarter were $4.7 million, down from $10.4 million in the same quarter last year, while general and administrative expenses decreased to $2.1 million from $3.1 million [8][9] - The net loss for the quarter was reported at $5.7 million, or $0.06 per share [9] Business Line Data and Key Metrics Changes - The decrease in operating expenses was primarily due to the completion of a large manufacturing campaign for blarcamesine and a reduction in clinical trial activities following the completion of the ANAVEX3-71 phase II study in schizophrenia [9] Market Data and Key Metrics Changes - The company is participating in the ACCESS-AD initiative, a European program aimed at accelerating the adoption of innovative diagnostic and therapeutic approaches for Alzheimer's disease [3][4] Company Strategy and Development Direction - The company is focused on advancing its clinical pipeline, particularly the lead candidate oral blarcamesine for early Alzheimer's disease, and is working with regulatory agencies in Europe and the U.S. to progress this treatment [3][4] - Anavex plans to provide updates on regulatory and clinical trial developments for blarcamesine in other indications, including Parkinson's disease and Fragile X [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of blarcamesine to improve the lives of patients with neurological disorders and emphasized the importance of scalable treatment options [10] - The company is committed to addressing the unmet needs in Alzheimer's disease and is preparing for a confirmatory study if approved under the conditional marketing authorization [51] Other Important Information - The company is planning to submit data from the phase IIB/III ANAVEX2-73-AD-004 program to the FDA and is working closely with the EMA for the re-examination of the marketing authorization application for blarcamesine [4][5] - New scientific findings related to blarcamesine will be presented at upcoming conferences and publications [6] Q&A Session Summary Question: Can you provide additional information regarding the rapporteur and co-rapporteur for the re-examination of the CHMP opinion on blarcamesine? - The rapporteurs will be selected from the 27 EU countries [15] Question: What is the timeline for the re-examination process? - The re-examination process is expected to last for the first half of the year, involving a 60 + 60 day period for responses and reviews [16] Question: When do you anticipate filing a formal NDA submission with the FDA? - The company plans to advance this once closer to the submission date, following productive discussions with the FDA [17] Question: What additional information will be included in the resubmission to the EMA? - The resubmission will include data from the AD-004 study, A-Clear study population, and correlations of clinical efficacy with brain atrophy reduction [24] Question: Are there any ongoing trials currently? - The only ongoing trials are compassionate use programs for Rett Syndrome and Alzheimer's Disease, with plans for studies in Parkinson's Disease and Fragile X [28] Question: How is blarcamesine involved in the ACCESS-AD program? - Blarcamesine will be evaluated in a placebo-controlled trial as part of the ACCESS-AD initiative, focusing on early Alzheimer's patients [51]

Anavex Life Sciences (NasdaqGS:AVXL) Q1 2026 Earnings call February 09, 2026 08:30 AM ET Speaker1Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2026 First Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session, and during this session if you would like to ask a question please use the Q&A box or raise your hand. Please note this confere ...

Core Insights - Caris Life Sciences will report its fourth quarter and full year 2025 financial results on February 26, 2026, and will host a conference call to discuss these results [1] Company Overview - Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, focused on developing and commercializing innovative healthcare solutions [2] - The company utilizes comprehensive molecular profiling, including Whole Genome, Whole Exome, and Whole Transcriptome Sequencing, combined with advanced AI and machine learning to analyze the molecular complexity of diseases [2] - Caris has established a large-scale, multimodal clinico-genomic database and computing capability, which supports the development of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection, and drug development [2] Company Background - Founded with the vision to harness the potential of precision medicine to enhance human health, Caris Life Sciences is headquartered in Irving, Texas, with additional offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland [3] - The company or its distributor partners provide services in the U.S. and various international markets [3]

Core Viewpoint - GE Medical Holding AB has exercised all its warrants in EXACT Therapeutics, resulting in gross proceeds of NOK 33 million, following a positive safety read-out from the phase 2 ENACT trial in locally advanced pancreatic cancer [1][2]. Group 1: Company Developments - EXACT Therapeutics announced that GE Medical Holding AB will exercise all of its 26,973,169 warrants, leading to gross proceeds of NOK 33 million for the company [2]. - The exercise of warrants is linked to the positive safety read-out from the ENACT phase 2 trial, which has encouraged further investment [2][5]. - The remaining warrant holders have until 26 February 2026 to exercise their warrants, with updates on the exercise expected to follow [2]. Group 2: Clinical Trial Insights - The ENACT phase 2 trial has shown early encouraging results, including significant tumor shrinkage and a decrease in the tumor biomarker CA 19-9 by over 85% [5]. - The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out, allowing the trial to proceed as planned [5]. Group 3: Company Background - EXACT Therapeutics is a clinical-stage precision medicine company that utilizes ultrasound to activate its proprietary drug PS101, enhancing the clinical benefits of oncology therapies [4]. - PS101 has a unique mode of action and can be combined with various therapeutic agents across multiple indications, including brain diseases [4].

HYDERABAD, India, Feb. 5, 2026 /PRNewswire/ -- According to Mordor Intelligence, the proteomics market size was valued at USD 29.92 billion in 2025 and projected to grow from USD 33.47 billion in 2026 to reach USD 58.66 billion by 2031, at a CAGR of 11.87% during the forecast period (2026-2031). The market expansion is supported by the growing focus on precision medicine, increasing prevalence of chronic diseases, and rising demand for advanced analytical tools to understand complex biological systems.  Th ...

We came across a bullish thesis on Tempus AI, Inc. on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on TEM. Tempus AI, Inc.'s share was trading at $64.57 as of January 28th. TEM’s trailing P/E was 41.53 according to Yahoo Finance. Morgan Stanley Lifted GE HealthCare Target to $80 in Late October, Citing Strong Orders and Backlog Wichy/Shutterstock.com Tempus AI, Inc. (NASDAQ: TEM) operates at the forefront of precision medicine, combining high-throughput genomic d ...